الفهرس | Only 14 pages are availabe for public view |
Abstract Anorexia, cachexia syndrome occurs in 30–80% of people with cancer referred to palliative care. It contributes to impaired quality of life (QoL), increased morbidity and mortality. Cyproheptadine hydrochloride (CH) is a histamine antagonist with appetite-stimulating effect. The probable mechanisms for appetite stimulating effect of this drug include constant increased energy intake through more desire to eating and stimulation of growth hormone secretion by deep sleep induction. Using CH improves the nutritional status in children with malnutrition in several studies The aim of this Study: evaluate the effect and tolerability of cyproheptadine in cancer associated anorexia and cachexia in cancer patients Materials and Methods: This randomized controlled clinical study was carried out in clinical oncology department, Menoufia University to evaluate the effect of cyproheptadine in cancer associated anorexia and cachexia in cancer patients treated in clinical oncology department, Menoufia University presented from january- 2022 to june -2022. 138 patients were recruited in the study and divided into 2 groups. Results: There was no significant difference among the studied groups regarding height, weight, and BMI, hb, albumin, Appetite score by FACCT, by ESAS and FACCT score at (baseline, 3, 6, 9, 12 months), ● In patients with non-metastatic stage, follow up Hb at (9 and 12 months) were significantly increased among drug arm. Moreover, follow up appetite score by FACCT at (9 and 12 Summary 96 months) were significantly increased among drug arm. Also, follow up appetite score by ESAS at (6, 9 and 12 months) significantly improves among drug arm. Regarding follow up of FACCT score at (9 and 12 months) there was significant increase among drug arm than control arm ● In patients with performance<2, follow up Hb at (6, 9 and 12 months) were significantly increased among drug arm Moreover, follow up appetite score by FACCT at (3, 6, 9 and 12 months) were significantly increased among drug arm. Also, follow up appetite score by ESAS at (6, 9 and 12 months) significantly improves among drug arm. Regarding follow up of FACCT score at (6, 9 and 12 months) there was significant increase among drug arm than control arm. ● In Patients with non GIT cancer, follow up Hb at 9 months was significantly increased among drug arm Moreover, follow up appetite score by ESAS at 12 months was significantly improves among drug arm ● In Patients who respond to active treatment, follow up Hb at (9 and 12 months) were significantly increased among drug arm. Moreover, follow up appetite score by ESAS at (9 and 12 months) were significantly improves among drug arm). Conclusion: Cypryheptadine is safe and tolerable and might be used in the treatment of cancer anorexia and cachexia syndrome provided that good selection of suitable patient regarding age, good performance status, early stage of cancer. |